Save up -80% on Sofosbuvir
Note: this is a drug discount program, not an insurance plan.
2018 Price of Sovaldi
* price without discount in nearest pharmacy. Price may vary.
We offer free Sofosbuvir coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Sofosbuvir every time. What are you waiting for? Claim your prescription drug card now!
Sofosbuvir volume of distribution
The volume of distribution for sofosbuvir has yet to be determined.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Sofosbuvir
Sofosbuvir is a prodrug nucleotide analog used as part of combination therapy to treat hepatitis C virus (HCV) infection or to treat co-infection of HIV and HCV. After metabolism to the active antiviral agent 2′-deoxy-2′- -fluoro- -C-methyluridine-5′-triphosphate (also known as GS-461203), the triphosphate serves as a defective substrate for the NS5B protein, an RNA-dependent RNA polymerase required for replication of viral RNA. Sofosbuvir and other nucleotide inhibitors of the HCV RNA polymerase exhibit a very high barrier to resistance development. This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid resistance development has proved to be an important cause of therapeutic failure. More recently, sofosbuvir has become available as a fixed dose drug combination product with levipasvir (tradename Harvoni) used for the treatment of chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Approved in October 2014 by the FDA, ledipasvir and sofosbuvir are direct-acting antiviral agents indicated for the treatment of HCV genotype 1 with or without cirrhosis. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States affecting 72% of all chronic HCV patients. Prior to development of this drug, the main treatment available was weekly injections of pegylated interferon with weight-based ribavirin over 48 weeks, which achieved a sustained virological response (SVR) of 45-50% and had multiple unpleasant side effects. When combined together, ledipasvir and sofosbuvir have been shown to have a SVR between 93 and 100% after 12 weeks of treatment. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV.
Sofosbuvir mechanism of action
Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B polymerase. Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase’s GDD active site motif.
Dosage forms of Sofosbuvir
S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate
Gilead Sciences Canada Inc
Hepatitis C virus, RSV and other RNA/DNA viruses
Indication of Sofosbuvir
Sofosbuvir is used in combination therapy to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptype 1,2,3, or 4, and to treat HCV and HIV co-infected patients. The combination therapy includes either ribavirin alone or ribavirin and peg-interferon alfa.
Toxicity of Sofosbuvir
Sofosbuvir, as a single agent, has very mild toxicity. The most common adverse reactions are headache and fatigue.
RX24 Drugs Disclaimer: before buying a Sofosbuvir on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.